Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing.

Morales-Molina A, Rodriguez-Milla MA, Gambera S, Cejalvo T, de Andres B, Gaspar ML, Garcia-Castro J
Cancer Res Commun. 2023 Mar 1;3(3):347-360. doi: 10.1158/2767-9764.CRC-22-0365. eCollection 2023 Mar. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.